PROT# AC220-002: Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients with Acute Myeloid Leukemia (AML) with FLT3-ITD Activating Mutations

Project: Research project

Project Details

StatusFinished
Effective start/end date7/7/108/31/17

Funding

  • PRA Health Sciences (AC220-002)
  • Ambit Biosciences Corporation (AC220-002)